Publicado por Ji Sikyeohaeng
ISBN 10: 8961090763 ISBN 13: 9788961090766
Librería: ThriftBooks-Atlanta, AUSTELL, GA, Estados Unidos de America
EUR 8,82
Cantidad disponible: 1 disponibles
Añadir al carritoPaperback. Condición: Very Good. No Jacket. May have limited writing in cover pages. Pages are unmarked. ~ ThriftBooks: Read More, Spend Less.
Librería: GreatBookPrices, Columbia, MD, Estados Unidos de America
EUR 111,58
Cantidad disponible: Más de 20 disponibles
Añadir al carritoCondición: New.
Librería: Ria Christie Collections, Uxbridge, Reino Unido
EUR 103,00
Cantidad disponible: Más de 20 disponibles
Añadir al carritoCondición: New. In.
Librería: Chiron Media, Wallingford, Reino Unido
EUR 100,29
Cantidad disponible: 10 disponibles
Añadir al carritoPF. Condición: New.
Librería: GreatBookPricesUK, Woodford Green, Reino Unido
EUR 102,99
Cantidad disponible: Más de 20 disponibles
Añadir al carritoCondición: New.
Librería: Kennys Bookshop and Art Galleries Ltd., Galway, GY, Irlanda
EUR 118,54
Cantidad disponible: 15 disponibles
Añadir al carritoCondición: New.
Librería: Books Puddle, New York, NY, Estados Unidos de America
EUR 143,95
Cantidad disponible: 4 disponibles
Añadir al carritoCondición: New. pp. 308 Reprint edition NO-PA16APR2015-KAP.
Librería: Kennys Bookstore, Olney, MD, Estados Unidos de America
EUR 146,68
Cantidad disponible: 15 disponibles
Añadir al carritoCondición: New.
EUR 86,20
Cantidad disponible: 5 disponibles
Añadir al carritoTaschenbuch. Condición: Neu. mTOR Inhibition for Cancer Therapy: Past, Present and Future | Monica Mita (u. a.) | Taschenbuch | vi | Englisch | 2016 | Springer | EAN 9782817805573 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu.
EUR 163,01
Cantidad disponible: 4 disponibles
Añadir al carritoCondición: New. pp. 400.
Librería: AHA-BUCH GmbH, Einbeck, Alemania
EUR 100,94
Cantidad disponible: 1 disponibles
Añadir al carritoTaschenbuch. Condición: Neu. Druck auf Anfrage Neuware - Printed after ordering - This book describes the challenges involved in developing mTOR inhibitors for cancer treatment, starting with an in-depth examination of their molecular mechanism of action, with emphasis on the class side-effects, efficacy and mechanisms of resistance, as well as on promising novel directions for their development, including novel compounds and rational combinations with other anti-neoplastic drugs. Over the last 10 years, inhibitors of mTOR have emerged as a major class of anticancer drugs. Two rapamycin analogs are currently approved for the treatment of renal cell carcinoma, and it is estimated that a variety of other tumor types could benefit from mTOR inhibition, with numerous clinical trials (including pivotal registration trials) already underway. Second-generation small-molecule inhibitors of the pathway have also shown promise in terms of their superior tolerability and efficacy and are undergoing extensive clinical evaluation, with an estimated 30+ compoundscurrently under evaluation.
Librería: Revaluation Books, Exeter, Reino Unido
EUR 138,86
Cantidad disponible: 2 disponibles
Añadir al carritoPaperback. Condición: Brand New. reprint edition. 300 pages. French language. 9.25x6.10x0.70 inches. In Stock.
Librería: AHA-BUCH GmbH, Einbeck, Alemania
EUR 111,53
Cantidad disponible: 1 disponibles
Añadir al carritoBuch. Condición: Neu. Druck auf Anfrage Neuware - Printed after ordering - This book describes the challenges involved in developing mTOR inhibitors for cancer treatment, starting with an in-depth examination of their molecular mechanism of action, with emphasis on the class side-effects, efficacy and mechanisms of resistance, as well as on promising novel directions for their development, including novel compounds and rational combinations with other anti-neoplastic drugs. Over the last 10 years, inhibitors of mTOR have emerged as a major class of anticancer drugs. Two rapamycin analogs are currently approved for the treatment of renal cell carcinoma, and it is estimated that a variety of other tumor types could benefit from mTOR inhibition, with numerous clinical trials (including pivotal registration trials) already underway. Second-generation small-molecule inhibitors of the pathway have also shown promise in terms of their superior tolerability and efficacy and are undergoing extensive clinical evaluation, with an estimated 30+ compoundscurrently under evaluation.
EUR 81,45
Cantidad disponible: 1 disponibles
Añadir al carritoCondición: Sehr gut. Zustand: Sehr gut | Seiten: 308 | Sprache: Englisch | Produktart: Bücher | This book describes the challenges involved in developing mTOR inhibitors for cancer treatment, starting with an in-depth examination of their molecular mechanism of action, with emphasis on the class side-effects, efficacy and mechanisms of resistance, as well as on promising novel directions for their development, including novel compounds and rational combinations with other anti-neoplastic drugs. Over the last 10 years, inhibitors of mTOR have emerged as a major class of anticancer drugs. Two rapamycin analogs are currently approved for the treatment of renal cell carcinoma, and it is estimated that a variety of other tumor types could benefit from mTOR inhibition, with numerous clinical trials (including pivotal registration trials) already underway. Second-generation small-molecule inhibitors of the pathway have also shown promise in terms of their superior tolerability and efficacy and are undergoing extensive clinical evaluation, with an estimated 30+ compoundscurrently under evaluation.
Librería: GreatBookPricesUK, Woodford Green, Reino Unido
EUR 187,82
Cantidad disponible: Más de 20 disponibles
Añadir al carritoCondición: As New. Unread book in perfect condition.
Librería: Mispah books, Redhill, SURRE, Reino Unido
EUR 178,32
Cantidad disponible: 1 disponibles
Añadir al carritoPaperback. Condición: Like New. Like New. book.
Librería: GreatBookPrices, Columbia, MD, Estados Unidos de America
EUR 210,85
Cantidad disponible: Más de 20 disponibles
Añadir al carritoCondición: As New. Unread book in perfect condition.
Librería: Brook Bookstore On Demand, Napoli, NA, Italia
EUR 86,24
Cantidad disponible: Más de 20 disponibles
Añadir al carritoCondición: new. Questo è un articolo print on demand.
Librería: Brook Bookstore On Demand, Napoli, NA, Italia
EUR 78,24
Cantidad disponible: Más de 20 disponibles
Añadir al carritoCondición: new. Questo è un articolo print on demand.
Idioma: Inglés
Publicado por Springer Paris Aug 2016, 2016
ISBN 10: 2817805577 ISBN 13: 9782817805573
Librería: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Alemania
EUR 96,29
Cantidad disponible: 2 disponibles
Añadir al carritoTaschenbuch. Condición: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -This book describes the challenges involved in developing mTOR inhibitors for cancer treatment, starting with an in-depth examination of their molecular mechanism of action, with emphasis on the class side-effects, efficacy and mechanisms of resistance, as well as on promising novel directions for their development, including novel compounds and rational combinations with other anti-neoplastic drugs. Over the last 10 years, inhibitors of mTOR have emerged as a major class of anticancer drugs. Two rapamycin analogs are currently approved for the treatment of renal cell carcinoma, and it is estimated that a variety of other tumor types could benefit from mTOR inhibition, with numerous clinical trials (including pivotal registration trials) already underway. Second-generation small-molecule inhibitors of the pathway have also shown promise in terms of their superior tolerability and efficacy and are undergoing extensive clinical evaluation, with an estimated 30+ compounds currently under evaluation. 308 pp. Englisch.
Idioma: Inglés
Publicado por Springer Paris Dez 2015, 2015
ISBN 10: 2817804910 ISBN 13: 9782817804910
Librería: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Alemania
EUR 106,99
Cantidad disponible: 2 disponibles
Añadir al carritoBuch. Condición: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -This book describes the challenges involved in developing mTOR inhibitors for cancer treatment, starting with an in-depth examination of their molecular mechanism of action, with emphasis on the class side-effects, efficacy and mechanisms of resistance, as well as on promising novel directions for their development, including novel compounds and rational combinations with other anti-neoplastic drugs. Over the last 10 years, inhibitors of mTOR have emerged as a major class of anticancer drugs. Two rapamycin analogs are currently approved for the treatment of renal cell carcinoma, and it is estimated that a variety of other tumor types could benefit from mTOR inhibition, with numerous clinical trials (including pivotal registration trials) already underway. Second-generation small-molecule inhibitors of the pathway have also shown promise in terms of their superior tolerability and efficacy and are undergoing extensive clinical evaluation, with an estimated 30+ compounds currently under evaluation. 308 pp. Englisch.
Librería: moluna, Greven, Alemania
EUR 81,44
Cantidad disponible: Más de 20 disponibles
Añadir al carritoCondición: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. First book on that topicInput and perspectives by international leadersPreclinical and clinical data available on the subject have been integratedA dedicated chapter on toxicity profile of mTOR inhibitorsFuture directions for .
Librería: moluna, Greven, Alemania
EUR 89,99
Cantidad disponible: Más de 20 disponibles
Añadir al carritoGebunden. Condición: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. First book on that topicInput and perspectives by international leadersPreclinical and clinical data available on the subject have been integratedA dedicated chapter on toxicity profile of mTOR inhibitorsFuture directions for .
Librería: Majestic Books, Hounslow, Reino Unido
EUR 146,31
Cantidad disponible: 4 disponibles
Añadir al carritoCondición: New. Print on Demand pp. 308.
Idioma: Inglés
Publicado por Springer, Springer Aug 2016, 2016
ISBN 10: 2817805577 ISBN 13: 9782817805573
Librería: buchversandmimpf2000, Emtmannsberg, BAYE, Alemania
EUR 96,29
Cantidad disponible: 1 disponibles
Añadir al carritoTaschenbuch. Condición: Neu. This item is printed on demand - Print on Demand Titel. Neuware -This book describes the challenges involved in developing mTOR inhibitors for cancer treatment, starting with an in-depth examination of their molecular mechanism of action, with emphasis on the class side-effects, efficacy and mechanisms of resistance, as well as on promising novel directions for their development, including novel compounds and rational combinations with other anti-neoplastic drugs.Over the last 10 years, inhibitors of mTOR have emerged as a major class of anticancer drugs. Two rapamycin analogs are currently approved for the treatment of renal cell carcinoma, and it is estimated that a variety of other tumor types could benefit from mTOR inhibition, with numerous clinical trials (including pivotal registration trials) already underway. Second-generation small-molecule inhibitors of the pathway have also shown promise in terms of their superior tolerability and efficacy and are undergoing extensive clinical evaluation, with an estimated 30+ compoundscurrently under evaluation.Springer-Verlag KG, Sachsenplatz 4-6, 1201 Wien 308 pp. Englisch.
Librería: Biblios, Frankfurt am main, HESSE, Alemania
EUR 149,04
Cantidad disponible: 4 disponibles
Añadir al carritoCondición: New. PRINT ON DEMAND pp. 308.
Librería: preigu, Osnabrück, Alemania
EUR 93,35
Cantidad disponible: 5 disponibles
Añadir al carritoBuch. Condición: Neu. mTOR Inhibition for Cancer Therapy: Past, Present and Future | Monica Mita (u. a.) | Buch | vi | Englisch | 2015 | Springer | EAN 9782817804910 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu Print on Demand.
Idioma: Inglés
Publicado por Springer, Springer Dez 2015, 2015
ISBN 10: 2817804910 ISBN 13: 9782817804910
Librería: buchversandmimpf2000, Emtmannsberg, BAYE, Alemania
EUR 106,99
Cantidad disponible: 1 disponibles
Añadir al carritoBuch. Condición: Neu. This item is printed on demand - Print on Demand Titel. Neuware -This book describes the challenges involved in developing mTOR inhibitors for cancer treatment, starting with an in-depth examination of their molecular mechanism of action, with emphasis on the class side-effects, efficacy and mechanisms of resistance, as well as on promising novel directions for their development, including novel compounds and rational combinations with other anti-neoplastic drugs.Over the last 10 years, inhibitors of mTOR have emerged as a major class of anticancer drugs. Two rapamycin analogs are currently approved for the treatment of renal cell carcinoma, and it is estimated that a variety of other tumor types could benefit from mTOR inhibition, with numerous clinical trials (including pivotal registration trials) already underway. Second-generation small-molecule inhibitors of the pathway have also shown promise in terms of their superior tolerability and efficacy and are undergoing extensive clinical evaluation, with an estimated 30+ compoundscurrently under evaluation.Springer-Verlag KG, Sachsenplatz 4-6, 1201 Wien 308 pp. Englisch.
Librería: Majestic Books, Hounslow, Reino Unido
EUR 166,17
Cantidad disponible: 4 disponibles
Añadir al carritoCondición: New. Print on Demand pp. 400 15 Illus. (Col.) This item is printed on demand.
Librería: Biblios, Frankfurt am main, HESSE, Alemania
EUR 167,91
Cantidad disponible: 4 disponibles
Añadir al carritoCondición: New. PRINT ON DEMAND pp. 400.